Human Genome Sciences, GlaxoSmithKline deal

GlaxoSmithKline completed its acquisition of Human Genome for $14.25 per share in cash, or about $3 billion. Following the initial close of the pharma's tender offer on July 30, GlaxoSmithKline replac...